Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29538286 | 1.00 | TDP1 (0.44) | TDP1LIPGCYP4F2CYP4A11HTR1A | |
| Hydrogen Peroxide SCHEMBL29092952 | 0.87 | LIPG (0.45) | LIPGHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL29488434 | 0.87 | ADRA2B (0.44) | LIPGHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL29534868 | 0.87 | TDP1 (0.55) | TDP1CYP4F2CYP4A11PTPN1 | |
| SCHEMBL31203 | 0.87 | TDP1 (0.55) | TDP1CYP4F2CYP4A11PTPN1 | |
| SCHEMBL142479 | 0.87 | ADRA2B (0.44) | LIPGHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL13552185 | 0.86 | LIPG (0.47) | LIPGCYP4F2CYP4A11HTR1AADRA2A | |
| SCHEMBL26240073 | 0.86 | LIPG (0.52) | TDP1LIPGCYP4F2CYP4A11PPARA | |
| SCHEMBL282444 | 0.85 | CYP4F2 (0.53) | LIPGCYP4F2CYP4A11HTR1AADRA2A | |
| SCHEMBL3022571 | 0.85 | GABRA1 (0.48) | TDP1CYP4F2CYP4A11GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| CN-109970760-B | ACC inhibitors and uses thereof | 吉利德阿波罗公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3628320-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| EP-3628320-A1 | ACC INHIBITORS AND USES THEREOF | Gilead Apollo, LLC (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-0406745-B1 | Antibiotic GE 2270 factors A1, A2, A3 and H | LEPETIT SPA (IT) | 1995-01-25 | — | — | EP | disclosed |
| US-5139778-A | ANTIBIOTIC GE 2270 FACTORS A1, A2, A3 AND H | GRUPPO LEPETIT SPA (IT) | 1992-08-18 | — | — | US | disclosed |
| EP-0146053-B1 | CHEMICAL PROCESS FOR PREPARING ANTIBIOTIC L 17392 (DEGLUCOTEICOPLANIN) AND ITS SALTS | GRUPPO LEPETIT S.p.A. (IT) | 1991-12-27 | — | — | EP | disclosed |
| EP-0240609-B1 | ANTIBIOTIC A 40926 N-ACYLAMINOGLUCURONYL AGLYCONS AND ANTIBIOTIC A 40926 AGLYCON | GRUPPO LEPETIT S.p.A. (IT) | 1991-12-04 | — | — | EP | disclosed |
| EP-0406745-A1 | Antibiotic GE 2270 factors A1, A2, A3 and H | GRUPPO LEPETIT S.p.A. (IT) | 1991-01-09 | — | — | EP | disclosed |
| US-4868171-A | Antibiotic A 40926 N-acylaminoglucuronyl aglycons and antiobiotic A 40926 aglycon | GRUPPO LEPETIT S.P.A. (IT) | 1989-09-19 | — | — | US | disclosed |
| EP-0240609-A2 | Antibiotic A 40926 N-acylaminoglucuronyl aglycons and antibiotic A 40926 aglycon | GRUPPO LEPETIT S.p.A. (IT) | 1987-10-14 | — | — | EP | disclosed |
| US-4629781-A | STRONG ACIDOLYSIS CONTROLLED BY THE USE OF SOLVENT, ACID, CONCENTRATION AND HEATING | GRUPPO LEPETIT S.P.A. (IT) | 1986-12-16 | — | — | US | disclosed |
| EP-0146053-A2 | Chemical process for preparing antibiotic L 17392 (Deglucoteicoplanin) and its salts | GRUPPO LEPETIT S.p.A. (IT) | 1985-06-26 | — | — | EP | disclosed |
| US-4317894-A | Low temperature cure coating compositions | PPG INDUSTRIES, INC. (US) | 1982-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | TDP1 3955/4885LIPG 397/4885CYP4F2 796/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | TDP1 3955/4885LIPG 397/4885CYP4F2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.